ticker: 4186.T layer: L0-Photoresist verdict: red verify_date: 2026-05-28 #

Tokyo Ohka Kogyo (4186.T) — Graham Value Screen #

Screened: 2026-05-28
Exchange: Tokyo Stock Exchange (JPX)
Sector: Technology / Specialty Chemicals
Layer: L0 — Photoresist (ArF/EUV photoresist global #1)
Employees: 2,132 (lean, high-value-add)

1. Price / 52-Week Data #

Abbreviated screen threshold NOT triggered (YTD 83.7% > 80% BUT price is -14.7% from 52w high, outside the 10% abbreviated cutoff). Full screen follows.

2. Valuation #

Critical flag: Forward P/E (55.8x) materially HIGHER than trailing P/E (39.2x). This means analysts expect FY2026 EPS to be JPY 195 — a -30% year-on-year earnings decline from the JPY 278 trailing figure. You would be buying at peak earnings, not trough earnings.

Peer comparison: | Company | Trailing P/E | P/B | Yield | |---|---|---|---| | TOK 4186.T | 39.2x | 3.19x | 0.73% | | Shin-Etsu Chemical 4063.T | 29.1x | 3.05x | 1.44% |

TOK trades at a premium to the largest Japanese specialty chemical company despite smaller scale. Premium is quality-priced, not trough-priced.

3. Balance Sheet (FY2025, Dec year-end) #

Note: Total debt rose from JPY 10.5B (2024) to JPY 26.5B (2025) — long-term debt issued JPY 20B to fund EUV capacity expansion. Still very conservative at 0.12x D/E. Net cash position remains positive. No solvency concern.

4. 5-Year Financial History #

Quality observations:

• Gross margin stability: 35.7–37.7% across the cycle including the 2023 trough. This is a moat indicator — pricing power in specialty chemicals.
• EBIT margin: 14–20%, improving. FY2023 trough (industry downcycle) still profitable at 14%.
• CapEx surge: 2.3x increase from JPY 11.4B (2022) to JPY 25.4B (2024-25) reflects EUV photoresist capacity investment. FCF is temporarily suppressed — this is growth investment, not deterioration.
• Revenue CAGR 2022-2025: +10.6% nominal, adjusted for 2023 downturn.
• Net income CAGR 2022-2025: +19.5% — scale leverage.
• ROE: 14.6% | ROA: 10.0% | ROIC: ~20.1% (excellent for a manufacturing compounder)

5. Dividend #

DPS CAGR 2021-2025: +8.5%. No cuts, no freezes through the 2023 downcycle. Next dividend: JPY 40 interim + JPY 40 final = JPY 80. Payout ratio 25.9% (sustainable).

At current price, yield 0.73% is well below the 5yr average of 1.8% — the stock has re-rated significantly faster than dividends grew. Another valuation signal.

6. Insider Activity #

Japanese TSE insider data not available via yfinance. From public filings:

• Founding family (Ohka group) holds ~9.2% — long-term alignment, no forced selling visible.
• 42.1% institutional (171 institutions): dominated by passive index ETFs (Vanguard, iShares EAFE, MSCI). No activist presence detected.
• No insider open-market purchase signals available (GREY per shr-002 framework).

7. Analyst Consensus #

• Mean rating: 2.1 (Buy)
• Consensus: Buy-leaning but 6 of 12 at Hold
• Target mean: JPY 10,900 (= current price — ZERO upside priced in at mean target)
• Target median: JPY 11,250 (+2%)
• Target high: JPY 14,300 (+30%)
• Target low: JPY 6,000 (-46%)

The wide spread (6,000 – 14,300) reflects genuine uncertainty about FY2026 earnings normalization vs structural EUV ramp thesis. Median analyst says "hold here."

8. Last 2 Earnings Reports #

Q4 FY2025 (January–March 2026, reported ~May 7 2026) #

• EPS actual: JPY 97.81
• Estimate: No consensus estimate available
• Revenue (Dec 2025 annual): JPY 237.0B (+17.9% YoY)
• Pattern: Fourth consecutive quarter of strong performance
• Signal: Fiscal year ending March 2026 was the company's strongest on record

Q3 FY2025 (October–December 2025, reported ~February 2026) #

• EPS actual: JPY 94.14 vs estimate JPY 75.28
• Surprise: +25.1% beat — the largest of the year
• Context: EUV photoresist demand accelerating; Samsung/TSMC ramp timing pulling forward

Earnings trajectory (FY2025): #

FY2025 quarterly EPS sum: JPY 313.32 (higher than Dec-year EPS of JPY 278 due to fiscal year mismatch).

Forward earnings outlook (FY2026 est. JPY 195): The -30% projected decline is significant. Possible reasons: (1) EUV qualification spending peaks and normalizes, (2) customer inventory digestion cycle, (3) yen normalization FX headwind, (4) conservative company guidance. This is the single biggest risk in the thesis.

9. News / Developments (90 days) #

• Sep 2025: Tokyo Ohka Kogyo joined JOINT3 Semiconductor Consortium — Japan's government-backed initiative for next-generation semiconductor manufacturing (alongside Rapidus, TSMC Japan, IMEC). Validates EUV/advanced photoresist strategic position.
• May 2026: Q4 FY2025 earnings release — strong close to the fiscal year.
• No negative catalysts visible in available news data (yfinance limited to Sep 2025 articles for Japanese stocks).

10. Cycle Position #

This is NOT a cyclical trough story. Key distinctions:

1. Structural growth, not cycle mean-reversion: ArF/EUV photoresist demand is driven by leading-edge capacity expansion at TSMC (N2, A16) and Samsung (SF2). This is an ongoing multi-year investment cycle, not a recovery from a demand trough.

2. Stock has already re-rated 2x YTD: The stock price reflects the structural thesis. It went from JPY ~6,000 in Jan 2026 to JPY 12,925 (52w high) — the market already recognized the EUV story.

3. Revenue growing, margins stable: 2023 was the industry downcycle (revenue -7.5%); 2024-2025 recovered strongly. The trough was 2023. Buying now is buying recovery + growth premium.

4. The forward earnings decline (FY2026 est -30%) is the market's acknowledgment that FY2025 was a peak earnings year (driven by pull-forward demand and favorable mix). The stock's 83% YTD move was partly anticipating this exceptional year.

5. No shr-017 INVERSE trap (peak multiple on peak earnings) — but the shr-017 warning does apply directionally: trailing metrics look excellent (Graham passes F1-F5) precisely because we are at/near peak earnings. Forward metrics reveal the normalization.

VWCE gap-fill thesis: The original framing — "VWCE holds limited Japanese semiconductor materials exposure, TOK fills that gap" — is structurally correct as a thesis. The flaw is valuation timing. The gap existed and was correctly identified; the fill has already happened in price.

Graham 7-Filter Screen #

Graham score: 5/7 (F6 and F7 fail)

Critical note on F6/F7 failure: This is NOT the shr-017 inverse trap (cyclical paying peak-cycle multiple). TOK is a genuine quality compounder. The F6/F7 failure reflects a structural quality premium — the market is paying for the moat, the EUV positioning, and the structural growth story. This is a different category of fail from a cyclical trough at peak earnings. However, the end result for Graham value investing is the same: no margin of safety exists at current price.

Graham Intrinsic Value (shr-003) #

Using Graham formula: V = EPS × (8.5 + 2g), adjusted for Japanese rates: V_adj = EPS × (8.5 + 2g) × (4.4 / 1.5) where 1.5% = Japan 10yr bond yield.

Trailing EPS: JPY 278 #

Break-even growth (Japan-adjusted): 2.5% — stock is fairly valued at trailing EPS assuming 2.5% long-term growth. At 3% growth, only 7% MOS (not compelling for a Graham position).

Forward EPS: JPY 195 (FY2026 analyst estimate — -30% from trailing) #

Break-even growth (Japan-adjusted, forward): 5.4% — at forward EPS, the stock requires 5.4% perpetual long-term growth just to reach fair value. At realistic structural growth of 7-8%, there is modest upside (+22-48%) but with no margin of safety buffer.

Implied growth from current multiple (shr-003) #

The market is implying 15–24% perpetual growth depending on which earnings base you use. For a specialty chemical manufacturer — even a photoresist leader — sustaining 15-24% growth for the long term is exceptionally demanding. The structural EUV story is real, but 15%+ priced-in growth leaves no room for error.

shr-020 Red Flag Check (2026-05-28) #

Summary: 3 GREEN | 3 AMBER | 2 RED | 2 GREY

Verdict #

VERDICT: RED

Summary rationale:

Tokyo Ohka Kogyo is a genuinely excellent business — global #1 in ArF/EUV photoresist, fortress balance sheet (net cash JPY +44.5B, D/E 0.12x), stable gross margins through cycles (35-38%), and a structural tailwind from TSMC/Samsung leading-edge capacity expansion. ROIC of ~20% confirms real economic moat. The VWCE gap-fill thesis (Japanese semiconductor materials underexposed in broad global index) is structurally sound.

The problem is price, not quality.

The stock has already rerated +194.8% in 52 weeks and +83.7% YTD. Every intelligent thesis that a thoughtful investor would construct — EUV moat, Japan semiconductor renaissance, JOINT3 consortium — was already constructed by the market and is reflected in JPY 12,925 (52w high). The current price JPY 11,030 is a -15% pullback from that fully-priced peak, not a trough.

The Graham IV analysis is unambiguous:

• At trailing EPS, the stock requires only 2.5% perpetual growth to be fairly valued (Japan-adjusted). At any reasonable structural growth assumption (5-10%), IV suggests upside — but the margin of safety above IV is minimal at 3% growth and the forward earnings picture undermines trailing EPS as a base.
• At forward EPS (JPY 195, -30% YoY), the stock requires 5.4% growth just to reach fair value. At 7.5% growth there is 22% upside — real but not compelling for a Graham buy.
• Implied growth from P/E is 15-24% — the market is pricing TOK as a high-growth technology compounder, not a value stock. For Graham criteria, this fails F6 and F7 emphatically.

The F6/F7 failures here are categorically different from shr-017 (cyclical trough misread). TOK passes F1-F5 because it IS a quality compounder — the failures reflect that the market fully prices the quality, leaving no defensive discount.

The forward earnings estimate (FY2026 JPY 195) is the kill shot. Analyst consensus expects earnings to decline -30% in the next fiscal year. Buying at 39.2x trailing earnings of a company where earnings are expected to fall is not a value investment — it is a growth-at-peak-earnings bet. Even if the long-term thesis is correct, the near-term risk/reward is poor.

Watchlist price: JPY 5,500–6,500 (approximately where forward IV at 5-7% growth has a 35-50% MOS on Japan-adjusted basis, and where dividend yield would recover to the 5yr average of 1.8%). This would require a ~40-50% drawdown from current levels — unlikely absent a broader Japan semi selloff or a negative EUV demand surprise.

Watchlist Alert Recommendation #

Do not enter. Set price alert at JPY 6,500 (below 5yr average dividend yield recovery level, forward IV at 5% growth, Japan-adj). Re-evaluate thesis if:

1. FY2026 earnings come in materially above JPY 195 (positive surprise on forward estimate)
2. Stock pulls back to JPY 6,000–7,000 range (prior Jan 2026 base before re-rating)
3. A confirmed large EUV photoresist supply contract is announced at below-current-price entry

VERDICT LINE: RED — Quality compounder, zero margin of safety. Peak earnings (FY2025), -30% forward EPS decline expected, P/E 39x trailing / 56x forward, P/B 3.2x, IV break-even requires only 2.5% growth (Japan-adj trailing) leaving no defensive buffer. Structural EUV thesis fully priced. Watchlist at JPY 6,500 (~-41% drawdown).